Clinical Trials
7 trialsNCT01458366 2025-04-30
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Thomas Jefferson University
Phase 1/2 Completed
NCT01060384 2023-10-04
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT01515176 2018-03-15
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01217749 2015-06-25
PCYC-1109-CA
Pharmacyclics LLC.
Phase 1/2 Completed
NCT00092274 2015-04-21
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
GlaxoSmithKline
Phase 1/2 Withdrawn
NCT00093314 2015-04-21
HuMax-CD20 in Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 1/2 Withdrawn
NCT01221103 2011-09-13
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Southern Europe New Drug Organization
Phase 1/2 Unknown